Alphamab Oncology (09966) reported its Monthly Return on Movements in Securities for the period ended January 31, 2026. The total authorized share capital remains 25,100,000,000 ordinary shares at a par value of USD 0.000002 each, amounting to USD 50,200 in total. There were no increases or decreases in authorized or issued share capital during this period.

The issued share count stood at 968,574,697 ordinary shares (excluding 5,719,000 held as treasury), making a total of 974,293,697 shares. No additional new shares were issued or transferred from treasury in January, and the company confirmed compliance with the minimum public float requirement. The company also disclosed details on existing share option schemes, noting no new share issuances arising from the options. The overall share structure and treasury share count remained unchanged.